文献速递甲状腺疾病

吸烟暴露与Graves病临床结局的剂量依赖性关联

Cigarette smoking exposure and clinical outcomes in Graves' disease.
PubMed 文献 · J Clin Endocrinol Metab · 2026-01-01

该单中心观察性队列研究纳入991例新诊断Graves病患者,分析吸烟状态与每日吸烟量与基线TRAb水平、眼病及停用抗甲状腺药物后复发的关系。结果显示当前吸烟者(27%)诊断时TRAb更高且眼病风险增加,每日每10支烟与眼病风险及12个月复发风险升高相关,戒烟者风险与非吸烟者相当。

要点

  • 当前吸烟者诊断时TRAb中位数7.8 vs 非吸烟者6.6 IU/L,眼病OR 1.76(95%CI 1.17-2.64)。
  • 每日每10支烟与眼病风险增加34%(95%CI 10-79%)及12个月复发风险增加60%相关。
  • 戒烟者风险与非吸烟者相当,支持戒烟或减量改善Graves病结局。

核心结论

  • 吸烟以剂量依赖方式与Graves病自身免疫活性增强、眼病风险升高及抗甲状腺药物停药后复发增加相关。
  • 戒烟者的风险与非吸烟者相当,支持将戒烟或减量作为改善Graves病结局的干预措施。

研究设计与样本

  • 单中心观察性队列研究,于英国二级内分泌科开展。
  • 连续纳入新诊断Graves病成人患者,诊断依据为TSH抑制、甲状腺激素升高及TRAb阳性或闪烁扫描弥漫性摄取增高。
  • 991例 eligible 患者纳入基线分析,663例完成ATD停药后≥12个月随访,712例纳入长期复发分析。

主要发现

  • 当前吸烟者占27%,诊断时TRAb中位数7.8 IU/L,非吸烟者为6.6 IU/L(P=.002)。
  • 当前吸烟者眼病 odds 增加(OR 1.76,95%CI 1.17-2.64)。
  • 每日每10支烟与眼病 odds 增加34%(95%CI 10-79%)及12个月复发风险增加60%相关。
  • 吸烟者ATD停药时TRAb更高。
  • 时间依赖Cox模型中,当前吸烟者超额复发风险在ATD停药后早期最大(6个月时HR 1.24),至2年时减弱。

临床怎么用

  • 对Graves病患者应评估吸烟状态及每日吸烟量,并将戒烟或减量作为改善眼病和复发风险的重要干预。
  • 当前吸烟者尤其需关注诊断时TRAb水平及眼病发生风险。
  • 当前吸烟者ATD停药后早期(6个月左右)复发风险最高,应加强此阶段监测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Smoking is a recognized risk factor for Graves' disease (GD), but its quantitative relationship with disease severity, autoimmunity, and relapse after antithyroid drug (ATD) therapy is unclear. OBJECTIVE: To evaluate the dose-dependent association between smoking exposure and key clinical outcomes in GD. METHODS: This was a single-center observational cohort study conducted in a secondary-care endocrinology unit in the United Kingdom. Consecutive adults with newly diagnosed GD confirmed by suppressed TSH, elevated thyroid hormones, and positive TRAb or diffusely increased scintigraphic uptake were analysed. All 991 eligible patients were included in baseline analyses; 663 completed ≥12 months follow-up after ATD cessation, and 712 contributed to long-term relapse analyses. The main outcome measures were baseline TRAb levels, presence of orbitopathy, and relapse at 12 months and long term, defined as recurrent biochemical hyperthyroidism with elevated TRAb after ATD withdrawal. Other outcomes included additional biochemical, scintigraphic and clinical measures. Exposures were smoking status (non-, ex-, current smoker) and cigarettes/day. RESULTS: Current smokers (27%) had higher TRAb levels at diagnosis (median 7.8 vs 6.6 IU/L in nonsmokers, P = .002) and increased odds of orbitopathy (OR 1.76, 95% CI 1.17-2.64). Each 10 cigarettes/day conferred a 34% (95% CI 10-79%) higher odds of orbitopathy and 60% higher 12-month relapse risk. Smokers also had higher TRAb at ATD cessation. In time-dependent Cox models, excess relapse risk among current smokers was greatest early after ATD withdrawal (HR 1.24 at 6 months) and diminished by 2 years. TRAb mediated only 7% of the smoking-relapse association. CONCLUSION: Smoking is associated with greater autoimmune activity, higher orbitopathy risk, and increased relapse in a dose-dependent manner. Ex-smokers have risks comparable with nonsmokers, supporting cessation or reduction as a meaningful intervention to improve GD outcomes.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Forbes S, Loo M, Tee SA, et al. Cigarette smoking exposure and clinical outcomes in Graves' disease. J Clin Endocrinol Metab. 2026. PMID: 41676894. doi:10.1210/clinem/dgag061

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。